TVGN vs. SNTI, COEP, PMCB, EVAX, APTO, AIM, CHRO, BCDA, GENE, and ONVO
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Senti Biosciences (SNTI), Coeptis Therapeutics (COEP), PharmaCyte Biotech (PMCB), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), BioCardia (BCDA), Genetic Technologies (GENE), and Organovo (ONVO). These companies are all part of the "biological products, except diagnostic" industry.
Senti Biosciences (NASDAQ:SNTI) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
Tevogen Bio has a net margin of 0.00% compared to Tevogen Bio's net margin of -2,692.82%. Senti Biosciences' return on equity of -21.83% beat Tevogen Bio's return on equity.
Senti Biosciences received 3 more outperform votes than Tevogen Bio when rated by MarketBeat users.
Tevogen Bio has lower revenue, but higher earnings than Senti Biosciences.
In the previous week, Senti Biosciences and Senti Biosciences both had 1 articles in the media. Tevogen Bio's average media sentiment score of 0.67 beat Senti Biosciences' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the media.
Senti Biosciences currently has a consensus target price of $6.00, indicating a potential upside of 1,609.40%. Given Tevogen Bio's higher probable upside, equities research analysts plainly believe Senti Biosciences is more favorable than Tevogen Bio.
25.7% of Senti Biosciences shares are held by institutional investors. 12.5% of Senti Biosciences shares are held by insiders. Comparatively, 56.6% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Senti Biosciences has a beta of 2.88, indicating that its stock price is 188% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
Summary
Senti Biosciences beats Tevogen Bio on 7 of the 12 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
